Host antitumor immunity plays a role in the survival of patients with newly diagnosed triple-negative breast cancer

Editorial

Sherene Loi. J Clin Oncol. 2014.

. 2014 Sep 20;32(27):2935-7.

doi: 10.1200/JCO.2014.56.7677.

No abstract available

Comment in

Reply to A. Ocaña et al and P.G. Tsoutsou et al.
Loi S. Loi S. J Clin Oncol. 2015 Apr 10;33(11):1299-300. doi: 10.1200/JCO.2014.59.9423. Epub 2015 Mar 9. J Clin Oncol. 2015. PMID: 25753442 No abstract available.

Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.
Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ, Wolff AC, Wood WC, Davidson NE, Sledge GW, Sparano JA, Badve SS. Adams S, et al. J Clin Oncol. 2014 Sep 20;32(27):2959-66. doi: 10.1200/JCO.2013.55.0491. J Clin Oncol. 2014. PMID: 25071121 Free PMC article.